|D001172||Arthritis, Rheumatoid NIH||0.30|
There is one clinical trial.
DETECTION OF THE 2019 NOVEL CORONAVIRUS (SARS-CoV-2) USING BREATH ANALYSIS- VALIDATION STUDY
Description: Comparison of Volatile Organic Compounds found among COVID-19 carriers and Healthy controls.Measure: Presence of Volatile Organic Compounds indicating carriers of COVID-19. Time: Through the study completion, up to 3 months.
Description: Correlation level between exhaled biomarkers and participants' demographic characteristics.Measure: Association of exhaled biomarkers with participants' characteristics (age, gender, symptoms-severity, etc.). Time: Through the study completion, up to 3 months.
Description: comparison of algorithm's sensitivity level to the sensitivity of COVID-19 swab TEST.Measure: sensitivity level of biomarkers' algorithm. Time: Through the study completion, up to 3 months.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports